Health Law & Business News

J&J ‘Cautiously Optimistic’ Vaccine Will Work on New Variants

Jan. 14, 2021, 1:36 AM

Johnson & Johnson’s expects its vaccine candidate will protect against new strains of the virus that causes Covid-19, the company said Wednesday.

“We are closely monitoring newly emerging variations in the SARS-CoV-2 Spike protein. Previous research has generated cautious optimism that the mutations leading to SARS-CoV-2 viral diversity should not be an obstacle for the broadly protective SARS-CoV-2 vaccine candidates currently in development,” the company said in a statement to Bloomberg Law.

J&J’s vaccine is largely expected to be the next in line to receive clearance from the Food and Drug Administration for emergency use during the public health emergency,...

To read the full article log in. To learn more about a subscription click here.